Ann Silk is an Oncology physician affiliated with Dana-Farber Cancer Institute. OpenAlex indexes 192 publications with 6,125 citations (h-index 34); ClinicalTrials.gov lists 4 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
450 Brookline Ave
Boston, MA 022155450
Telephone
617-632-6140Registry record last updated 14 Feb 2019.
Clinical trials
- Cosibelimab for CSCC in Patients With Kidney Transplant or Hematologic Malignancy
Sponsor: Dana-Farber Cancer Institute
- A Study of Tolododekin Alfa (ANK-101) in Renal Allograft Recipients With High Risk Cutaneous Squamous Cell Carcinoma
Sponsor: Ankyra Therapeutics, Inc
- Troriluzole or Placebo Plus Ipi Plus Nivo in Mel Brain Mets
Sponsor: Dana-Farber Cancer Institute
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
9 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- SUN PHARMACEUTICAL INDUSTRIES INC.Program year202526 payments$27,863openpaymentsdata.cms.gov ↗
- Regeneron Healthcare Solutions, Inc.Program year202531 payments$25,957openpaymentsdata.cms.gov ↗
- Immunocore LimitedProgram year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
NIH funding
1 NIH research award on record, funded 2026–2026 per NIH RePORTER. The latest:
- The Fourth International Merkel Cell Carcinoma Symposium
Dana-Farber Cancer Inst
FY2026$25,000R13AR088535
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Challenges and opportunities in cancer immunotherapy: a Society for Immunotherapy of Cancer (SITC) strategic vision
Journal for ImmunoTherapy of Cancer
2024 - Cemiplimab for Kidney Transplant Recipients With Advanced Cutaneous Squamous Cell Carcinoma
Journal of Clinical Oncology
2024 - Neoadjuvant-Intent Immunotherapy in Advanced, Resectable Cutaneous Squamous Cell Carcinoma
JAMA Otolaryngology–Head & Neck Surgery
2024
Similar KOLs
Other experts from the same institution or the same specialty.
Kenneth Anderson, MD
Dana-Farber Cancer Institute
Paul Richardson, MD
Dana-Farber Cancer Institute
Toni Choueiri, MD
Dana-Farber Cancer Institute
Pasi Janne, MD, PhD
Dana-Farber Cancer Institute
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”